158 related articles for article (PubMed ID: 14769850)
1. Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes.
Voo KS; Fu T; Wang HY; Tellam J; Heslop HE; Brenner MK; Rooney CM; Wang RF
J Exp Med; 2004 Feb; 199(4):459-70. PubMed ID: 14769850
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr virus nuclear antigen 1-specific CD4+ T cells directly kill Epstein-Barr virus-carrying natural killer and T cells.
Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
Cancer Sci; 2008 Aug; 99(8):1633-42. PubMed ID: 18754877
[TBL] [Abstract][Full Text] [Related]
3. Targeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses.
Gurer C; Strowig T; Brilot F; Pack M; Trumpfheller C; Arrey F; Park CG; Steinman RM; Münz C
Blood; 2008 Aug; 112(4):1231-9. PubMed ID: 18519810
[TBL] [Abstract][Full Text] [Related]
4. Dual non-contiguous peptide occupancy of HLA class I evoke antiviral human CD8 T cell response and form neo-epitopes with self-antigens.
Xiao Z; Ye Z; Tadwal VS; Shen M; Ren EC
Sci Rep; 2017 Jul; 7(1):5072. PubMed ID: 28698575
[TBL] [Abstract][Full Text] [Related]
5. The SPPL3-Defined Glycosphingolipid Repertoire Orchestrates HLA Class I-Mediated Immune Responses.
Jongsma MLM; de Waard AA; Raaben M; Zhang T; Cabukusta B; Platzer R; Blomen VA; Xagara A; Verkerk T; Bliss S; Kong X; Gerke C; Janssen L; Stickel E; Holst S; Plomp R; Mulder A; Ferrone S; Claas FHJ; Heemskerk MHM; Griffioen M; Halenius A; Overkleeft H; Huppa JB; Wuhrer M; Brummelkamp TR; Neefjes J; Spaapen RM
Immunity; 2021 Jan; 54(1):132-150.e9. PubMed ID: 33271119
[TBL] [Abstract][Full Text] [Related]
6. Translating DRiPs: MHC class I immunosurveillance of pathogens and tumors.
Antón LC; Yewdell JW
J Leukoc Biol; 2014 Apr; 95(4):551-62. PubMed ID: 24532645
[TBL] [Abstract][Full Text] [Related]
7. Targeting Proteasomes and the MHC Class I Antigen Presentation Machinery to Treat Cancer, Infections and Age-Related Diseases.
Rana PS; Ignatz-Hoover JJ; Driscoll JJ
Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067336
[TBL] [Abstract][Full Text] [Related]
8. MHC class I dimer formation by alteration of the cellular redox environment and induction of apoptosis.
Makhadiyeva D; Lam L; Moatari M; Vallance J; Zheng Y; Campbell EC; Powis SJ
Immunology; 2012 Feb; 135(2):133-9. PubMed ID: 22044191
[TBL] [Abstract][Full Text] [Related]
9. Amsterdamming DRiPs.
Yewdell JW
Mol Immunol; 2013 Sep; 55(2):110-2. PubMed ID: 23266429
[TBL] [Abstract][Full Text] [Related]
10. Toward a Network Model of MHC Class II-Restricted Antigen Processing.
Miller MA; Ganesan AP; Eisenlohr LC
Front Immunol; 2013 Dec; 4():464. PubMed ID: 24379819
[TBL] [Abstract][Full Text] [Related]
11. Sequence variation of the Epstein-Barr virus nuclear antigen 1 (EBNA1) gene in chronic lymphocytic leukemia and healthy volunteer subjects.
Vafapour Z; Tabatabaie FH; Hosseini SY; Haghighat S; Hashemi SMA; Moattari A; Sarvari J
Arch Virol; 2023 Dec; 169(1):1. PubMed ID: 38063941
[TBL] [Abstract][Full Text] [Related]
12. EBV-induced T-cell responses in EBV-specific and nonspecific cancers.
Zhang Q; Xu M
Front Immunol; 2023; 14():1250946. PubMed ID: 37841280
[TBL] [Abstract][Full Text] [Related]
13. Type I arginine methyltransferases are intervention points to unveil the oncogenic Epstein-Barr virus to the immune system.
Angrand G; Quillévéré A; Loaëc N; Dinh VT; Le Sénéchal R; Chennoufi R; Duchambon P; Keruzoré M; Martins RP; Teulade-Fichou MP; Fåhraeus R; Blondel M
Nucleic Acids Res; 2022 Nov; 50(20):11799-11819. PubMed ID: 36350639
[TBL] [Abstract][Full Text] [Related]
14. Interplay between IL-10, IFN-γ, IL-17A and PD-1 Expressing EBNA1-Specific CD4
Forconi CS; Mulama DH; Saikumar Lakshmi P; Foley J; Otieno JA; Kurtis JD; Berg LJ; Ong'echa JM; Münz C; Moormann AM
Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771539
[TBL] [Abstract][Full Text] [Related]
15. Induction of EBV latent membrane protein-2A (LMP2A)-specific T cells and construction of individualized TCR-engineered T cells for EBV-associated malignancies.
Zhang C; Tan Q; Li S; Shen L; Zhang J; Liu Y; Yang W; Lu Z
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34210819
[TBL] [Abstract][Full Text] [Related]
16. Virus-specific T cells for malignancies - then, now and where to?
Sharma S; Leung WK; Heslop HE
Curr Stem Cell Rep; 2020 Jun; 6(2):17-29. PubMed ID: 33738181
[TBL] [Abstract][Full Text] [Related]
17. The Critical Role of Genome Maintenance Proteins in Immune Evasion During Gammaherpesvirus Latency.
Sorel O; Dewals BG
Front Microbiol; 2018; 9():3315. PubMed ID: 30687291
[TBL] [Abstract][Full Text] [Related]
18. Macavirus latency-associated protein evades immune detection through regulation of protein synthesis in cis depending upon its glycin/glutamate-rich domain.
Sorel O; Chen T; Myster F; Javaux J; Vanderplasschen A; Dewals BG
PLoS Pathog; 2017 Oct; 13(10):e1006691. PubMed ID: 29059246
[TBL] [Abstract][Full Text] [Related]
19. High Levels of IL-10 and CD4+CD25hi+ Treg Cells in Endemic Burkitt's Lymphoma Patients.
Futagbi G; Gyan B; Nunoo H; Tetteh JKA; Welbeck JE; Renner LA; Ofori M; Dodoo D; Edoh DA; Akanmori BD
Biomedicines; 2015 Aug; 3(3):224-236. PubMed ID: 28536409
[TBL] [Abstract][Full Text] [Related]
20. Immune targets and neoantigens for cancer immunotherapy and precision medicine.
Wang RF; Wang HY
Cell Res; 2017 Jan; 27(1):11-37. PubMed ID: 28025978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
